Chronic Intestinal Pathologies Analytical Cohort at TouLouse (CAPITOL)

Toulouse University Hospital

Status

Enrolling

Conditions

Colon Cancer

Inflammatory Bowel Diseases

Treatments

Biological: blood and intestinal biopsy sampling

Study type

Observational

Funder types

Other

Identifiers

NCT04896684

RC31/21/0038

Details and patient eligibility

About

In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool will be studied. The aim of this project is to build a biological collection with associated clinical data for research projects.

Full description

In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, two of them namely inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) will be more particularly studied. This interest is based on the increasing frequency of these two pathologies, their chronicities but above all the limited physiopathological data available. In addition, it seems interesting to study a third population, namely patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool. The study of this population is part of an improvement in knowledge on the carcinogenesis of colorectal cancer.

To study these populations, blood, serum, plasma and tissues from colonous biopsies or surgical samples will be collected.

This cohort will make it possible to study, among other things, the pathophysiology of chronic diseases of the small intestine and the colon (IBD, IBS, screening) in order to improve their management through the development of new biomarkers and therapeutic targets.

Enrollment

300 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient requiring endoscopic explorations for screening or follow-up in the context of a suspected IBS or IBD or colorectal cancer Or
Patient with IBD requiring surgical management
Patient over 18 years old
Patient able to read and understand the information leaflet
Patients who have given their consent to participate in the study
Patients affiliated to a social security system (including AME)

Exclusion criteria

Patients who have received antibiotic treatments in the 10 days preceding endoscopic exploration
Pregnant or breastfeeding patients
Patients under 18 years old
Patients under guardianship or curatorship
Patients unable to sign a free and informed consent